NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Captial Report
Ipca Laboratories Ltd.’s Q2 FY25 sales and operating performance came in line with estimates while adjsuted profit after tax came above, after adjusting for forex loss.
For FY25, the company maintained its revenue growth guidance of around 9-10% on standalone basis and further upgraded Ebitda margin guidance to 22% from 21%.
We revise our FY25E/FY26E EPS estimates by 1.2%/-0.5. We roll over to FY27 and upgrade to ‘Accumulate’ rating from Reduce at 30 times FY27 P/E with a revised target price of Rs 1,718.
Click on the attachment to read the full report:
Also Read: Bharat Forge Q2 Results Review - Weak Demand In Core Segments Hurts Earnings: Motilal Oswal
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
.png?rect=0%2C0%2C3500%2C1969&w=75)
Hero MotoCorp Q2 Results Review - Inline Operating Performance: Motilal Oswal
Nov 18, 2024
RateGain Q2 Review - Results Beat But Lowers FY25 Guidance On Weak Deal Wins: Dolat Capital
Nov 14, 2024
Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix
Nov 12, 2024
NHPC Q2 Results Review - A Muted Quarter; Upgrade To 'Reduce' From 'Sell': ICICI Securities
Nov 11, 2024
POPULAR